Repeat Skin Cancer Risk with Methotrexate and Biologics Save
Using Medicare claims data, a retrospective cohort study analyzed the risk of a second non-melanomatous skin cancer (NMSC) in 9460 individuals (6841 with RA and 2788 with IBD).
The overall incidence rate of a second NMSC was roughly the same for RA and IBD patients, 58.2 per 1000 person-years and 58.9/1000PY in IBD, respectively.
In RA, methotrexate use for 1 year or more was associated with an increased risk of a second NMSC (HR 1.24; 95% CI, 1.04-1.48).
Compared to methotrexate alone, the addition of TNF inhibitors was also associated with a significantly higher risk of NMSC (HR, 1.49; 95% CI, 1.03-2.16).
No increased risk for a second NMSC was seen with abatacept and rituximab in RA. A nonsignificant trend was seen with INB patients treated with >1 years of thiopurine or anti-TNF inhibitors 1.49 (95% CI, 0.98-2.27) and 1.36 (95% CI, 0.76-2.44), respectively.
These data were generated in RA and IBD patients with incident NMSC seen between 2006-2012 who had at least 12 months follow up after the discovery of their first NMSC.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.